Medopa en es it fr

Medopa Brand names, Medopa Analogs

Medopa Brand Names Mixture

  • No information avaliable

Medopa Chemical_Formula

C56H71N9O23S

Medopa RX_link

http://www.rxlist.com/cgi/generic4/mycamine.htm

Medopa fda sheet

Medopa FDA

Medopa msds (material safety sheet)

Medopa MSDS

Medopa Synthesis Reference

No information avaliable

Medopa Molecular Weight

1270.28 g/mol

Medopa Melting Point

No information avaliable

Medopa H2O Solubility

Freely soluble as sodium salt (> 200mg/mL)

Medopa State

Solid

Medopa LogP

No information avaliable

Medopa Dosage Forms

Powder for solution (for injection)

Medopa Indication

For use in the treatment of patients with esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

Medopa Pharmacology

Formerly known as FK463, micafungin is a novel antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.

Medopa Absorption

No information avaliable

Medopa side effects and Toxicity

Intravenous LD50 in rats is 125mg/kg. In dogs it is >200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.

Medopa Patient Information

No information avaliable

Medopa Organisms Affected

Aspergillis, Candida and other fungi